Cystic Fibrosis Transmembrane Conductance Regulator
CFTRproteinCFTR dysfunction impairs sphingosine-1-phosphate degradation, exacerbating post-MI inflammation.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleModulates S1P signaling and post-MI inflammatory responses.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates13
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000001626
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I37
C — confounder / Type-II82
A — assay feasibility72
E — evidence strength30
T1DI (composite)6
Specificity differential (R−C)-44.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Therapeutic CFTR Correction Normalizes Systemic and Lung-Specific S1P Level Alterations Associated with Heart Failure.International journal of molecular sciences · 2022 · PMID 35055052 · doi